Extraordinary Meeting Announcement for Calliditas Therapeutics AB
Calliditas Therapeutics AB (publ) invites its shareholders to attend an extraordinary general meeting where key company matters will be discussed. This meeting will be held at the offices of Advokatfirman Vinge in the near future, reflecting our dedication to transparency and active shareholder involvement.
Context for the Meeting
Recently, Asahi Kasei Corporation made a public offer that has been accepted, resulting in their ownership of over 90% of Calliditas Therapeutics shares. In light of this, Asahi Kasei has called for this extraordinary meeting to address important agenda items. They will propose resolutions concerning agenda items 7-11 during the session.
Shareholder Participation Rights
Shareholders who wish to attend the meeting must be listed in the share register by a specified date. To notify us of your participation, please send your details by mail or email, including personal information and the number of guests accompanying you. If you plan to attend by proxy, a written authorization must be provided.
Nominee-Registered Shares
Shareholders holding nominee-registered shares must ensure their shares are registered in their own name to be eligible to attend. This can be achieved temporarily by submitting a request for voting rights registration.
Share Information
Currently, there are 54,033,447 ordinary shares eligible for voting, along with 5,908,018 shares held by the company itself, which do not confer voting rights at the meeting. This totals 59,941,465 shares, but only the 54,033,447 shares will be represented during the meeting.
Meeting Agenda
- Opening of the meeting
- Election of a chairman for the meeting
- Preparation and approval of the voting register
- Approval of the meeting agenda
- Election of one or two individuals to approve the meeting minutes
- Confirmation of proper meeting convening
- Determination of the number of board members
- Election and removal of board members as necessary
- Setting of board member fees
- Decision on the principles for the nomination committee following delisting
- Resolution on guidelines for group management remuneration after delisting
- Closing remarks of the meeting
Chairman Election for the Meeting
The nomination committee has put forward Dain Hård Nevonen as the recommended chairman for this general meeting, ensuring a well-organized and productive session.
Shareholder Rights to Information
During the meeting, shareholders have the right to ask questions of the board of directors and the CEO. To facilitate this, questions can be submitted in advance via post or email to ensure they are addressed during the discussions.
Additional Information for Attendees
Proxy forms are available at the company's headquarters and can also be downloaded from the corporate website. We recommend obtaining these forms well ahead of time to ensure smooth registration at the meeting.
Data Protection Practices
For information regarding the handling of personal data, shareholders can refer to the privacy policy on the Euroclear website, which underscores our commitment to safeguarding personal information.
Conclusion of Meeting Notice
We strongly encourage all shareholders to attend this important event that will influence the future direction and governance of Calliditas Therapeutics AB. The board is eager to engage with shareholders during this meeting.
Frequently Asked Questions
What is the purpose of the extraordinary meeting?
The meeting is intended to discuss significant agenda items in light of recent changes in ownership and adjustments in corporate governance.
How can shareholders participate in the meeting?
Shareholders need to register their participation and ensure their nominations are properly aligned to be eligible to vote.
Who will lead the extraordinary meeting?
Dain Hård Nevonen has been nominated to serve as the chairman, overseeing the meeting proceedings.
Can shareholders ask questions during the meeting?
Absolutely, shareholders have the right to ask questions and seek information related to the discussions and decisions made during the meeting.
Where can I find more information about the meeting?
Additional details, including the agenda and other relevant notes, will be accessible on the company's website and at their headquarters prior to the meeting date.
